Tuesday
On 23 March 2012, St Jude Medical announced it has received FDA clearance for multiple enhancements to its PressureWire fractional flow reserve (FFR) measurement guidewire. FFR measurement identifies the severity of narrowings in the coronary arteries and allows for a more effective assessment of coronary lesions, resulting in more accurate diagnosis and improved appropriate treatment of coronary artery blockages.
Monday
Noncardiac health issues, including chronic kidney disease and frailty, were responsible for a fairly high death rate at four years in older high-risk patients who underwent transcatheter aortic valve implantation (TAVI), researchers found. Half of the 339 patients in the study were dead by 48 months, and the numbers were equally split among those who had the procedure performed transfemorally or transapically, reported Josep Rodés-Cabau, MD, from the Quebec Heart & Lung Institute.
Sunday
Saturday
Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia. TruVue s diagnostic benefits include the ability to: record and wirelessly transmit every heartbeat for up to 30 days; perform advanced arrhythmia analysis; and to provide immediate online access to all transmitted ECG.
Boston Scientific has announced the exercise of its option to acquire Cameron Health which is the developer of the world’s first and only commercially available subcutaneous implantable cardioverter defibrillator – the S-ICD system.
Baxter has announced that it has started a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischaemia.
Biosense Webster has announced that a study it is sponsoring, the Atrial Fibrillation Progression Trial (ATTEST), has started to enrol patients and will investigate the impact of early radiofrequency ablation on the progression of drug-refractory paroxysmal atrial fibrillation to persistent atrial fibrillation.
A study published online in the HeartRhythm Journal indicates that while the sodium channel blocker test has good prognostic value in symptomatic patients with non-diagnostic Brugada ECG (Br-ECG), it appears to have little value in asymptomatic patients.
The US Food and Drug Administration (FDA) has granted Priority Review designation to the supplemental $ew Drug Application (s$DA) for rivaroxaban (Xarelto, Bayer) in combination with standard antiplatelet therapy to reduce the risk of (thrombotic) cardiovascular events in patients with acute coronary syndrome. The application was filed on 29 December 2011.
Eight-month results of the Valentines Trial II global registry have shown that the Dior drug-eluting balloon is a safe and effective treatment for cases of de novo coronary lesions. The follow-up data were presented at Cardiovascular Research Technologies (CRT2012) in Washington, USA, by Antonio Serra, Barcelona, Spain.
Boston Scientific’s Ion Paclitaxel-Eluting Platinum Chromium Coronary Stent System and Taxus Liberte Paclitaxel-Eluting Coronary Stent System have received FDA approval for use in patients experiencing an acute myocardial infarction on 22 February 2012. They are the only drug-eluting stent systems in the USA with an approved indication to treat patients with acute myocardial infarction.
Medtronic announced on 17 February 2012 FDA approval of the Resolute Integrity drug-eluting stent for the treatment of coronary artery disease. The new heart device’s FDA approval stems from the results of a global series of studies involving the Resolute drug-eluting stent, which showed consistently powerful clinical performance across a broad spectrum of patients––including those with diabetes. The Resolute Integrity uses the same drug-and-polymer combination as the Resolute device.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos